ARS Pharmaceuticals, Inc.
SPRY
$9.72
-$0.08-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 22,367.80% | 971,120.00% | 297,063.33% | 8,460.00% | 128.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22,367.80% | 971,120.00% | 297,063.33% | 8,460.00% | 128.31% |
| Cost of Revenue | 15.95% | 2.76% | 2.45% | -1.22% | -12.18% |
| Gross Profit | 603.70% | 512.75% | 442.34% | 13.73% | 13.65% |
| SG&A Expenses | 288.09% | 142.86% | 50.95% | -16.32% | -1.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 199.95% | 100.28% | 36.54% | -12.04% | -5.48% |
| Operating Income | -4.59% | 56.34% | 95.43% | 15.59% | 5.96% |
| Income Before Tax | -6.44% | 69.09% | 115.24% | 20.32% | 15.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.08% | 68.51% | 114.71% | 20.32% | 15.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.08% | 68.51% | 114.71% | 20.32% | 15.94% |
| EBIT | -4.59% | 56.34% | 95.43% | 15.59% | 5.96% |
| EBITDA | -3.63% | 56.86% | 95.55% | 15.59% | 5.97% |
| EPS Basic | -4.44% | 69.26% | 113.92% | 28.41% | 39.29% |
| Normalized Basic EPS | -3.01% | 65.49% | 107.84% | 20.79% | 32.56% |
| EPS Diluted | -24.22% | 51.52% | 97.80% | 28.41% | 39.29% |
| Normalized Diluted EPS | -21.15% | 49.10% | 92.32% | 20.79% | 32.56% |
| Average Basic Shares Outstanding | 1.51% | 1.62% | 1.81% | 9.54% | 33.70% |
| Average Diluted Shares Outstanding | 7.18% | 7.32% | 7.54% | 9.54% | 33.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |